留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

心脏移植的发展现状和新挑战

陈良万, 李虔桢, 戴小福, 等. 心脏移植的发展现状和新挑战[J]. 器官移植, 2023, 14(1): 31-41. doi: 10.3969/j.issn.1674-7445.2023.01.004
引用本文: 陈良万, 李虔桢, 戴小福, 等. 心脏移植的发展现状和新挑战[J]. 器官移植, 2023, 14(1): 31-41. doi: 10.3969/j.issn.1674-7445.2023.01.004
Chen Liangwan, Li Qianzhen, Dai Xiaofu, et al. Development status and new challenges of heart transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 31-41. doi: 10.3969/j.issn.1674-7445.2023.01.004
Citation: Chen Liangwan, Li Qianzhen, Dai Xiaofu, et al. Development status and new challenges of heart transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 31-41. doi: 10.3969/j.issn.1674-7445.2023.01.004

心脏移植的发展现状和新挑战

doi: 10.3969/j.issn.1674-7445.2023.01.004
基金项目: 

国家自然科学基金联合基金项目 U2005202

福建省科技厅创新联合基金项目 2020Y9067

详细信息
    作者简介:
    通讯作者:

    陈良万,Email:chenliangwan@tom.com

  • 中图分类号: R617, R541

Development status and new challenges of heart transplantation

More Information
  • 摘要: 心脏移植是终末期心力衰竭患者的首选治疗。供者不足一直以来都是限制心脏移植数量增长的主要问题,随着新技术的不断更新和引入,供者池被不断扩大,比如使用年龄较大的供者、丙型肝炎病毒感染的供者、毒品过量致死的供者或心脏死亡器官捐献(DCD)供者的心脏等。与此同时,高龄、多器官功能不全、机械循环支持及人类白细胞抗原抗体致敏受者的比例近几年明显增加。供者数量的不足、受者状况的复杂化、免疫抑制治疗的个体化管理和远期移植物血管病的防治等都是心脏移植领域面临的挑战。本文通过概述现今全球在扩大供者库、提高受者质量、加强排斥反应的诊治和心脏移植物血管病变的预防等方面的新进展,以期有助于改善在等待或已经接受心脏移植的终末期心力衰竭患者的生存时间和生活质量。

     

  • [1] MCDONAGH TA, METRA M, ADAMO M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. DOI: 10.1093/eurheartj/ehab368.
    [2] KHUSH KK, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1056-1066. DOI: 10.1016/j.healun.2019.08.004.
    [3] KHUSH KK, POTENA L, CHERIKH WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics[J]. J Heart Lung Transplant, 2020, 39(10): 1003-1015. DOI: 10.1016/j.healun.2020.07.010.
    [4] JOHN MM, SHIH W, ESTEVEZ D, et al. Interaction between ischemic time and donor age on adult heart transplant outcomes in the modern era[J]. Ann Thorac Surg, 2019, 108(3): 744-748. DOI: 10.1016/j.athoracsur.2019.03.042.
    [5] JAWITZ OK, RAMAN V, KLAPPER J, et al. Donor and recipient age matching in heart transplantation: analysis of the UNOS Registry[J]. Transpl Int, 2019, 32(11): 1194-1202. DOI: 10.1111/tri.13481.
    [6] STEHLIK J, FELDMAN DS, BROWN RN, et al. Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis[J]. J Heart Lung Transplant, 2010, 29(3): 291-298. DOI: 10.1016/j.healun.2009.08.007.
    [7] GOLAND S, CZER LS, KASS RM, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool[J]. J Am Coll Cardiol, 2008, 51(12): 1214-1220. DOI: 10.1016/j.jacc.2007.11.052.
    [8] WOOLLEY AE, SINGH SK, GOLDBERG HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients[J]. N Engl J Med, 2019, 380(17): 1606-1617. DOI: 10.1056/NEJMoa1812406.
    [9] ASLAM S, GROSSI P, SCHLENDORF KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement[J]. J Heart Lung Transplant, 2020, 39(5): 418-432. DOI: 10.1016/j.healun.2020.03.004.
    [10] DOULAMIS IP, TZANI A, MOUSTAKIDIS S, et al. Effect of hepatitis C donor status on heart transplantation outcomes in the United States[J]. Clin Transplant, 2021, 35(4): e14220. DOI: 10.1111/ctr.14220.
    [11] CRESPO-LEIRO MG, COSTANZO MR, GUSTAFSSON F, et al. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies[J]. Eur Heart J, 2022, 43(23): 2237-2246. DOI: 10.1093/eurheartj/ehac204.
    [12] HUCKABY LV, SEESE LM, HANDZEL R, et al. Center-level utilization of hepatitis C virus-positive donors for orthotopic heart transplantation[J]. Transplantation, 2021, 105(12): 2639-2645. DOI: 10.1097/TP.0000000000003674.
    [13] DEFILIPPIS EM, KHUSH KK, FARR MA, et al. Evolving characteristics of heart transplantation donors and recipients: JACC focus seminar[J]. J Am Coll Cardiol, 2022, 79(11): 1108-1123. DOI: 10.1016/j.jacc.2021.11.064.
    [14] MULVIHILL MS, COX ML, BISHAWI M, et al. Decline of increased risk donor offers on waitlist survival in heart transplantation[J]. J Am Coll Cardiol, 2018, 72(19): 2408-2409. DOI: 10.1016/j.jacc.2018.07.097.
    [15] VIEIRA JL, CHERIKH WS, LINDBLAD K, et al. Cocaine use in organ donors and long-term outcome after heart transplantation: an International Society for Heart and Lung Transplantation registry analysis[J]. J Heart Lung Transplant, 2020, 39(12): 1341-1350. DOI: 10.1016/j.healun.2020.08.018.
    [16] QUADER M, TOLDO S, CHEN Q, et al. Heart transplantation from donation after circulatory death donors: present and future[J]. J Card Surg, 2020, 35(4): 875-885. DOI: 10.1111/jocs.14468.
    [17] DHITAL KK, IYER A, CONNELLAN M, et al. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series[J]. Lancet, 2015, 385(9987): 2585-2591. DOI: 10.1016/S0140-6736(15)60038-1.
    [18] MESSER S, CERNIC S, PAGE A, et al. A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors[J]. J Heart Lung Transplant, 2020, 39(12): 1463-1475. DOI: 10.1016/j.healun.2020.10.001.
    [19] FARR M, TRUBY LK, LINDOWER J, et al. Potential for donation after circulatory death heart transplantation in the United States: retrospective analysis of a limited UNOS dataset[J]. Am J Transplant, 2020, 20(2): 525-529. DOI: 10.1111/ajt.15597.
    [20] WANG L, MACGOWAN GA, ALI S, et al. Ex situ heart perfusion: the past, the present, and the future[J]. J Heart Lung Transplant, 2021, 40(1): 69-86. DOI: 10.1016/j.healun.2020.10.004.
    [21] OU R, LIM YW, CHOONG JW, et al. Low-flow hypothermic crystalloid perfusion is superior to cold storage during prolonged heart preservation[J]. Transplant Proc, 2014, 46(10): 3309-3313. DOI: 10.1016/j.transproceed.2014.09.149.
    [22] WICOMB WN, COOPER DK, NOVITZKY D, et al. Cardiac transplantation following storage of the donor heart by a portable hypothermic perfusion system[J]. Ann Thorac Surg, 1984, 37(3): 243-248. DOI: 10.1016/s0003-4975(10)60333-5.
    [23] NILSSON J, JERNRYD V, QIN G, et al. A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation[J]. Nat Commun, 2020, 11(1): 2976. DOI: 10.1038/s41467-020-16782-9.
    [24] IYER A, GAO L, DOYLE A, et al. Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors[J]. Am J Transplant, 2015, 15(2): 371-380. DOI: 10.1111/ajt.12994.
    [25] ARDEHALI A, ESMAILIAN F, DENG M, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED Ⅱ): a prospective, open-label, multicentre, randomised non-inferiority trial[J]. Lancet, 2015, 385(9987): 2577-2584. DOI: 10.1016/S0140-6736(15)60261-6.
    [26] GARCÍA SÁEZ D, ZYCH B, SABASHNIKOV A, et al. Evaluation of the organ care system in heart transplantation with an adverse donor/recipient profile[J]. Ann Thorac Surg, 2014, 98(6): 2099-2105. DOI: 10.1016/j.athoracsur.2014.06.098.
    [27] BALIGA RR. Genetically modified porcine-to-human cardiac xenotransplantation[J]. N Engl J Med, 2022, 387(14): 1337-1338. DOI: 10.1056/NEJMc2210401.
    [28] JAISWAL A, GADELA NV, BARAN D, et al. Clinical outcomes of older adults listed for heart transplantation in the United States[J]. J Am Geriatr Soc, 2021, 69(9): 2507-2517. DOI: 10.1111/jgs.17271.
    [29] CHAMBERS DC, CHERIKH WS, GOLDFARB SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation[J]. J Heart Lung Transplant, 2018, 37(10): 1169-1183. DOI: 10.1016/j.healun.2018.07.020.
    [30] GALLO M, TRIVEDI JR, SCHUMER EM, et al. Combined heart-kidney transplant versus sequential kidney transplant in heart transplant recipients[J]. J Card Fail, 2020, 26(7): 574-579. DOI: 10.1016/j.cardfail.2020.03.002.
    [31] KITAI T, OKAMOTO T, MIYAKOSHI C, et al. Impact of combined heart and lung transplantation on bronchiolitis obliterans syndrome, cardiac allograft vasculopathy, and long-term survival[J]. J Heart Lung Transplant, 2019, 38(11): 1170-1177. DOI: 10.1016/j.healun.2019.06.004.
    [32] DALY RC, ROSENBAUM AN, DEARANI JA, et al. Heart-after-liver transplantation attenuates rejection of cardiac allografts in sensitized patients[J]. J Am Coll Cardiol, 2021, 77(10): 1331-1340. DOI: 10.1016/j.jacc.2021.01.013.
    [33] RIZVI SA, LUC JGY, CHOI JH, et al. Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis[J]. Ann Cardiothorac Surg, 2018, 7(1): 12-18. DOI: 10.21037/acs.2018.01.09.
    [34] 陈良万, 廖崇先, 陈道中, 等. 心脏移植后16年行再次心脏移植一例[J]. 中华器官移植杂志, 2013, 34(10): 607-610. DOI: 10.3760/cma.j.issn.0254-1785.2013.10.008.

    CHEN LW, LIAO CX, CHEN DZ, et al. One case of heart retransplantation 16 years after primary heart transplantation[J]. Chin J Organ Transplant, 2013, 34(10): 607-610. DOI: 10.3760/cma.j.issn.0254-1785.2013.10.008.
    [35] SUN YF, WANG ZW, ZHANG J, et al. Current status of and opinions on heart transplantation in China[J]. Curr Med Sci, 2021, 41(5): 841-846. DOI: 10.1007/s11596-021-2444-9.
    [36] BARGE-CABALLERO E, ALMENAR-BONET L, GONZALEZ-VILCHEZ F, et al. Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry[J]. Eur J Heart Fail, 2018, 20(1): 178-186. DOI: 10.1002/ejhf.956.
    [37] YIN MY, WEVER-PINZON O, MEHRA MR, et al. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices[J]. J Heart Lung Transplant, 2019, 38(8): 858-869. DOI: 10.1016/j.healun.2019.04.003.
    [38] KORMOS RL, COWGER J, PAGANI FD, et al. The Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientific partnerships[J]. J Heart Lung Transplant, 2019, 38(2): 114-126. DOI: 10.1016/j.healun.2018.11.013.
    [39] MEHRA MR, URIEL N, NAKA Y, et al. A fully magnetically levitated left ventricular assist device - final report[J]. N Engl J Med, 2019, 380(17): 1618-1627. DOI: 10.1056/NEJMoa1900486.
    [40] JORDE UP, KUSHWAHA SS, TATOOLES AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support)[J]. J Am Coll Cardiol, 2014, 63(17): 1751-1757. DOI: 10.1016/j.jacc.2014.01.053.
    [41] MEHRA MR, CLEVELAND JC JR, URIEL N, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2 200 HeartMate 3 left ventricular assist device implants[J]. Eur J Heart Fail, 2021, 23(8): 1392-1400. DOI: 10.1002/ejhf.2211.
    [42] DENG MC, EISEN HJ, MEHRA MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling[J]. Am J Transplant, 2006, 6(1): 150-160. DOI: 10.1111/j.1600-6143.2005.01175.x.
    [43] KOBASHIGAWA J, PATEL J, AZARBAL B, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial[J]. Circ Heart Fail, 2015, 8(3): 557-564. DOI: 10.1161/CIRCHEARTFAILURE.114.001658.
    [44] DALY KP. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection?[J]. Ann Transl Med, 2015, 3(4): 47. DOI: 10.3978/j.issn.2305-5839.2015.01.35.
    [45] CRESPO-LEIRO M, HILLER D, WOODWARD R, et al. Analysis of donor-derived cell-free DNA with 3-year outcomes in heart transplant recipients[J]. J Heart Lung Transplant, 2017, 36(4): S69-S70. DOI: org/ 10.1016/j.healun.2017.01.172.
    [46] KOBASHIGAWA J, MILLER L, RENLUND D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. mycophenolate mofetil investigators[J]. Transplantation, 1998, 66(4): 507-515. DOI: 10.1097/00007890-199808270-00016.
    [47] LAUNAY M, GUITARD J, DORENT R, et al. Belatacept-based immunosuppression: a calcineurin inhibitor-sparing regimen in heart transplant recipients[J]. Am J Transplant, 2020, 20(2): 553-563. DOI: 10.1111/ajt.15584.
    [48] MILLER CL, MADSEN JC. IL-6 directed therapy in transplantation[J]. Curr Transplant Rep, 2021, 8(3): 191-204. DOI: 10.1007/s40472-021-00331-4.
    [49] GARBERS C, HEINK S, KORN T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine[J]. Nat Rev Drug Discov, 2018, 17(6): 395-412. DOI: 10.1038/nrd.2018.45.
    [50] KOBASHIGAWA JA, TOBIS JM, STARLING RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years[J]. J Am Coll Cardiol, 2005, 45(9): 1532-1537. DOI: 10.1016/j.jacc.2005.02.035.
  • 加载中
图(1)
计量
  • 文章访问数:  34
  • HTML全文浏览量:  4
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-11-11
  • 网络出版日期:  2023-01-17
  • 刊出日期:  2023-01-15

目录

    /

    返回文章
    返回